Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control.
Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control.
复制标题
DOI：
10.1038/emm.2015.76
复制
发表时间：
2015-08-28
影响因子：
12.8
通讯作者：
Choi S
中科院分区：
文献类型：
--
作者：
Durai P;Batool M;Shah M;Choi S
中东呼吸综合征冠状病毒(MERS-CoV)引起高烧、咳嗽、急性呼吸道感染和多器官功能障碍，最终可能导致感染者死亡。MERS冠状病毒被认为是通过单峰骆驼传播给人类的。据报道，该病毒首先在中东出现，随后蔓延到世界几个地区。自2012年以来，全球已报告约1368例感染，包括约487例死亡。值得注意的是，最近MERS-CoV在韩国医院在人与人之间的“超级传播”引发了一个重大的全球健康问题。与密切相关的严重急性呼吸综合征冠状病毒感染相比，MERS冠状病毒感染的病死率高出四倍。目前，还没有药物被临床批准用于控制MERS冠状病毒感染。在这项研究中，我们重点介绍了可用于开发抗MERS冠状病毒疗法的潜在药物靶点。
Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~487 deaths, have been reported worldwide. Notably, the recent human-to-human ‘superspreading' of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.